Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +4.67%58 Current Ratio is 6.53 as of Mar. 2026, which is 56% above its 10-year median of 4.19. GuruFocus rates BGLC with a GF Score™ of 58/100 and a GF Value™ of $2.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,606 Chemicals companies, BioNexus Gene Lab ranks better than 91.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BioNexus Gene Lab's current ratio for the quarter that ended in Mar. 2026 was 6.53.
BioNexus Gene Lab has a current ratio of 6.53. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BioNexus Gene Lab's Current Ratio or its related term are showing as below:
BGLC'
s Current Ratio Range Over the Past 10 Years
Min: 2.37 Med: 4.19 Max: 20.6
Current: 6.53
During the past 8 years, BioNexus Gene Lab's highest Current Ratio was 20.60. The lowest was 2.37. And the median was 4.19.
BGLC's Current Ratio is ranked better than 91.53% of 1606
companies
in the Chemicals industry
Industry Median: 1.89
vs BGLC: 6.53
BioNexus Gene Lab (NAS:BGLC) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BioNexus Gene Lab Current Ratio Related Terms
BioNexus Gene Lab Current Ratio Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs QGAI, VYST, GLGI: Current Ratio Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Current Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Current Ratio distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Current Ratio of 6.53 as of Mar. 2026. This is 56% above median its historical median of 4.19. Over the past decade, BioNexus Gene Lab's Current Ratio has ranged from 2.37 to 20.60. According to the industry distribution chart, BioNexus Gene Lab ranks #136 out of 1606 companies in the Chemicals industry, placing it in the top 8.5%.
Is BioNexus Gene Lab's Current Ratio too high?
BioNexus Gene Lab's current Current Ratio of 6.53 is 56% above median its 10-year median of 4.19. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 20.60. The Chemicals industry median Current Ratio is 1.89. BioNexus Gene Lab's value of 6.53 is 245.5% above this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #136 out of 1606 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Current Ratio compare to QGAI and VYST?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #136 out of 1606 companies for Current Ratio. This places BioNexus Gene Lab in the top 9% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.89. BioNexus Gene Lab's value of 6.53 is 245.5% above this benchmark. Historically, BioNexus Gene Lab's own Current Ratio has ranged from 2.37 to 20.60 over the past decade. While the company's 10-year median is 4.19 vs. the industry median of 1.89, BioNexus Gene Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Chemicals company?
The median Current Ratio among Chemicals companies is 1.89, based on 1,606 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Current Ratio of 6.53 is 245.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median Current Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Current Ratio is 6.53, which is 56% above median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current Current Ratio is 6.53, which is 56% above median its 10-year median of 4.19 and 245.5% above the Chemicals industry median of 1.89. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Current Ratio is 6.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Current Ratio: 6.53 (56% above median its 10-year median of 4.19)
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
Industry Position: 245.5% above the Chemicals median (#136 of 1606)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
